Apramycin

Overview

Apramycin is an orally administered aminoglycoside antibiotic primarily used in food-producing animals for the treatment of bacterial enteritis. It has no approved or recommended therapeutic use in dogs or cats.

In companion animals, apramycin is considered inappropriate due to safety concerns and lack of clinical indication. The drug is contraindicated in cats, and there are no established indications, dosing recommendations, or efficacy data supporting its use in dogs.

Although apramycin is generally poorly absorbed from the gastrointestinal tract, partial systemic absorption may occur, particularly in neonates, increasing the theoretical risk of aminoglycoside-associated toxicity (eg, nephrotoxicity, ototoxicity). For these reasons, and because safer and better-studied alternatives exist, apramycin should not be used in small animal practice.

Additionally, apramycin is no longer commercially available in the United States, further limiting its relevance for dogs and cats.

Indications

There are no approved or recommended indications for apramycin in dogs or cats.

Apramycin is an orally administered aminoglycoside intended for the treatment of bacterial enteritis in food-producing species. It has no established therapeutic role in companion animals, and no clinical efficacy or dosing data are available to support its use in dogs or cats.

In addition, apramycin is contraindicated in cats and is not recommended in dogs due to lack of indication, limited absorption data, and the availability of safer, better-studied antimicrobial alternatives for small animal patients.

Dosages

There are no established, approved, or recommended dosages of apramycin for dogs or cats.

Apramycin is an orally administered aminoglycoside intended for use in food-producing animals only. The source provides dosing information exclusively for calves, pigs, poultry, rabbits, and other non–companion animal species.

In small animal practice:

• Dogs:
  No dosage has been established. Use is not recommended due to lack of efficacy data and potential toxicity.
• Cats:
  Apramycin is contraindicated and must not be used.

Because of the absence of safe dosing guidelines and the potential for aminoglycoside-associated nephrotoxicity and ototoxicity if systemically absorbed, apramycin should not be administered to dogs or cats.

Warnings & Precautions

Apramycin is not indicated for use in dogs or cats and should generally be avoided in small animal practice due to safety concerns, lack of efficacy data, and the availability of safer alternatives.

• Cats:
  Apramycin is contraindicated in cats. Use may pose a significant risk of aminoglycoside-associated toxicity, including nephrotoxicity and ototoxicity.
• Dogs:
  There are no approved or recommended indications or dosages for apramycin in dogs. Its use is not supported by clinical data in this species.
• Renal disease:
  Contraindicated in animals with kidney disorders. Aminoglycosides have the potential to cause nephrotoxicity if systemically absorbed.
• Systemic absorption:
  Although apramycin is primarily intended for oral use with minimal absorption, partial systemic absorption may occur, especially in neonates, increasing the risk of toxicity.
• Lack of feeding:
  Because apramycin is administered orally (in feed or water in food animals), it would be ineffective in animals that are not eating or drinking.
• Availability:
  Apramycin is no longer commercially available in the United States, further limiting its clinical relevance for dogs and cats.

DOSAGE NOTE: There are no established, safe, or recommended dosage regimens for apramycin in dogs or cats. Use in these species is not advised.

Drug Interactions

There are no specific drug interaction studies for apramycin in dogs or cats. The following interactions are extrapolated from information reported for orally administered aminoglycosides (eg, neomycin) and are included for theoretical and safety awareness only.

Because apramycin is not recommended for use in dogs and is contraindicated in cats, concurrent administration with other drugs should be avoided.

• Ototoxic or nephrotoxic drugs:
  Concurrent use may increase the risk of kidney or inner ear toxicity if systemic absorption occurs.
• Neuromuscular-blocking agents:
  Aminoglycosides may potentiate neuromuscular blockade, potentially leading to muscle weakness or respiratory compromise.
• Cephalosporins:
  Concurrent use may enhance nephrotoxic potential.
• Cyclosporine:
  May increase the risk of nephrotoxicity when used with aminoglycosides.
• Digoxin (oral):
  Oral aminoglycosides may alter digoxin absorption or serum concentrations; clinical significance in dogs and cats is unknown.
• Mannitol:
  Concurrent use may enhance nephrotoxic effects.
• Methotrexate:
  Oral aminoglycosides may reduce gastrointestinal absorption.
• Vitamin K antagonists:
  Alteration of intestinal vitamin K absorption may theoretically affect anticoagulant activity.

Given the lack of indication, safety data, and dosing guidance in dogs and cats, apramycin should not be coadministered with other medications in these species.

Side Effects & Overdose

Apramycin is not intended for use in dogs or cats; therefore, adverse effects and overdose information in these species are limited and based on theoretical risk and extrapolation from aminoglycoside pharmacology.

Side Effects

• Cats:
  Apramycin is contraindicated. Use may pose a high risk of aminoglycoside-associated toxicity.
• Dogs:
  No documented adverse effects at therapeutic doses because no approved or recommended use exists.
• Nephrotoxicity (theoretical):
  If systemic absorption occurs, especially in young or compromised patients, kidney injury may develop, as with other aminoglycosides.
• Ototoxicity (theoretical):
  Damage to the inner ear with potential hearing loss or vestibular dysfunction is possible with systemic exposure.
• GI effects:
  Oral aminoglycosides may cause mild gastrointestinal disturbances, though this has not been specifically documented in dogs or cats for apramycin.

Overdose / Acute Toxicity

• Dogs and cats:
  No overdose studies or safe upper limits have been established.
• Theoretical overdose effects:
  Excessive systemic exposure could result in severe nephrotoxicity, ototoxicity, or neuromuscular blockade, consistent with aminoglycoside toxicity.
• Management:
  Immediately discontinue exposure and provide supportive care. Renal function should be closely monitored.
• Consultation:
  For suspected overdose or adverse reactions, consultation with a veterinary poison control center is recommended.

Due to the absence of safety data and the availability of safer alternatives, apramycin should not be used in dogs or cats.

Keynotes

• Food-animal drug:
  Apramycin is designed for use in food-producing species and has no therapeutic role in companion animals.
• Small-animal relevance:
  There are no approved indications or dosing guidelines for dogs, and the drug must not be used in cats.
• Systemic risk:
  Although intended for oral use with limited absorption, aminoglycoside-class toxicity is a concern if absorption occurs.
• Regulatory limitations:
  The drug is no longer commercially available in the United States, further limiting clinical applicability.
• Clinical takeaway:
  Safer, better-studied antimicrobial alternatives should always be selected for dogs and cats.